A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).

Natalie Yan Li NgoiValerie HeongSamuel OwWen Yee ChayHee Seung KimChel Hun ChoiGeraldine GossJeffrey C GohBee Choo TaiDiana Gz LimNivashini KaliaperumalVeonice B AuJohn E ConnollyJae-Weon KimMichael FriedlanderKidong KimDavid Sp Tan

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)

Clinicaltrials.gov: NCT03405454.

Keyphrases

phase ii
clear cell
locally advanced
clinical trial
double blind
open label
primary care
emergency department
placebo controlled
squamous cell carcinoma
phase iii
rectal cancer
cross sectional
radiation therapy
decision making